Lenvatinib is a novel AZGP1 agonist candidate for ICC that inhibits ICC-EMT by regulating the TGF-β1/Smad3 signaling pathway in an AZGP1-dependent manner. This evidence concerns the gene TGFB1 and intrahepatic cholangiocarcinoma.